One in Five Back Pain Patients Experience Persistent Pain
MONDAY, Jan. 14, 2019 -- Eighteen percent of patients with back pain experience a persistent trajectory, according to a study published online Jan. 14 in Arthritis Care & Research.
Mayilee Canizares, Ph.D., from the Krembil Research Institute at the University Health Network in Toronto, and colleagues followed a representative sample of the Canadian population (12,782 individuals) from 1994 to 2011. Participants were interviewed biannually and provided data on sociodemographic factors, behavior-related factors, depression, comorbidities, pain, disability, medication use, and health care use. Participants were grouped based on patterns of the course of back pain during follow-up.
The researchers found that during follow-up, 45.6 percent of patients reported back pain at least once. Of these, four trajectories were identified: persistent, developing, recovery, and occasional (18.0, 28.1, 20.5, and 33.4 percent, respectively). More pain preventing activities, disability, depression, and comorbidities characterized the persistent and developing groups. Across the groups, significant differences were seen in the patterns of medication and health care use, with a general trend of most to least use in the persistent, developing, recovery, and occasional use groups. An increasing trajectory of opioid and antidepressant use was seen in the recovery group.
"The results have important implications for the way we understand back pain as the different trajectory patterns potentially represent subgroups in the population that may require different interventions," the authors write.
One author disclosed financial ties to Medtronic.
© 2020 HealthDay. All rights reserved.
Posted: January 2019
More News Resources
- FDA Medwatch Drug Alerts
- Daily MedNews
- News for Health Professionals
- New Drug Approvals
- New Drug Applications
- Drug Shortages
- Clinical Trial Results
- Generic Drug Approvals
- Monthly Update Archive
Subscribe to our Newsletter
Whatever your topic of interest, subscribe to our newsletters to get the best of Drugs.com in your inbox.